BR0316724A - Compounds, use of one or more compounds, and process for the manufacture of pharmaceutical compositions - Google Patents

Compounds, use of one or more compounds, and process for the manufacture of pharmaceutical compositions

Info

Publication number
BR0316724A
BR0316724A BR0316724-0A BR0316724A BR0316724A BR 0316724 A BR0316724 A BR 0316724A BR 0316724 A BR0316724 A BR 0316724A BR 0316724 A BR0316724 A BR 0316724A
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical compositions
manufacture
preparation
general formula
Prior art date
Application number
BR0316724-0A
Other languages
Portuguese (pt)
Inventor
Martin Bolli
Christoph Boss
Martine Clozel
Walter Fischli
Thomas Weller
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR0316724A publication Critical patent/BR0316724A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to novel sulfamic acid amides of General Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
BR0316724-0A 2002-12-02 2003-11-10 Compounds, use of one or more compounds, and process for the manufacture of pharmaceutical compositions BR0316724A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP0213601 2002-12-02
EP03778307A EP1569914B1 (en) 2002-12-02 2003-11-10 Pyrimidine-sulfamides and their use as endothelian receptor antagonist
PCT/EP2003/012502 WO2004050640A1 (en) 2002-12-02 2003-11-10 Pyrimidine-sulfamides and their use as endothelian receptor antagonist

Publications (1)

Publication Number Publication Date
BR0316724A true BR0316724A (en) 2005-10-18

Family

ID=32405666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316724-0A BR0316724A (en) 2002-12-02 2003-11-10 Compounds, use of one or more compounds, and process for the manufacture of pharmaceutical compositions

Country Status (18)

Country Link
US (1) US7452896B2 (en)
EP (1) EP1569914B1 (en)
JP (1) JP4769460B2 (en)
KR (1) KR101063042B1 (en)
CN (1) CN100379730C (en)
AT (1) ATE423103T1 (en)
AU (1) AU2003285321B2 (en)
BR (1) BR0316724A (en)
CA (1) CA2507334C (en)
DE (1) DE60326263D1 (en)
ES (1) ES2320649T3 (en)
IL (1) IL168836A (en)
MX (1) MXPA05005793A (en)
NO (1) NO20052520L (en)
NZ (1) NZ540937A (en)
RU (1) RU2329255C2 (en)
WO (1) WO2004050640A1 (en)
ZA (1) ZA200505109B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100739367B1 (en) 2004-07-14 2007-07-16 크리스탈지노믹스(주) Sulfamide derivatives and pharmaceutical composition for upregulation of lipid metabolism containing same
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
FR2878523B1 (en) * 2004-11-30 2007-09-14 Oreal NOVEL SULFAMID DERIVATIVES AND THEIR COSMETIC USE
US7887824B2 (en) 2004-11-30 2011-02-15 L'oreal Sulfamide derivatives and cosmetic use thereof
WO2006081190A2 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
WO2008090970A1 (en) * 2007-01-26 2008-07-31 Panasonic Corporation Stereo encoding device, stereo decoding device, and their method
EP2142505A1 (en) * 2007-04-03 2010-01-13 Pfizer, Inc. Sulfonamides and pharmaceutical compositions thereof
MX2010001837A (en) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Iron with actively cooled soleplate and method for cooling the soleplate.
WO2010032261A1 (en) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
CN102099026B (en) 2008-08-13 2012-08-29 埃科特莱茵药品有限公司 Therapeutic compositions containing macitentan
CN103724281A (en) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 Novel derivative of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl and application of novel derivative
WO2019101039A1 (en) * 2017-11-21 2019-05-31 南京明德新药研发股份有限公司 Pyrimidine sulfamide derivative and preparation method and medical application thereof
CN108997223B (en) * 2018-08-09 2020-06-30 浙江先锋科技股份有限公司 Preparation method of 5- (4-bromophenyl) -4, 6-dichloropyrimidine
CN109232546B (en) * 2018-09-25 2020-09-04 中国人民解放军总医院 Medical application of pyrimidine sulfonamide derivative
RU2763899C1 (en) * 2021-03-26 2022-01-11 федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации Sodium salt of 4-{ 2-[2-(4- hydroxy-3-methoxyphenyl)-vinyl]-6-ethyl-4-oxo-5-phenyl-4h-pyrimidine-1-yl} -benzenesulfamide, which has an antitumor effect

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1549494A (en) 1967-10-31 1968-12-13
DE2801584A1 (en) 1978-01-14 1979-07-19 Bayer Ag HALOGEN-SUBSTITUTED PYRIMIDIN (2) YL-THIONO-THIOL-PHOSPHOR (PHOSPHONE) - ACID ESTERS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS INSECTICIDES AND ACARICIDES
RU2086544C1 (en) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
TW313568B (en) 1994-12-20 1997-08-21 Hoffmann La Roche
JP3013752B2 (en) * 1995-05-16 2000-02-28 田辺製薬株式会社 Sulfonamide derivative
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
DE69612874T2 (en) 1995-12-20 2001-10-04 Yamanouchi Pharma Co Ltd ARYLETHENE SULFONAMIDE DERIVATIVES AND MEDICINES CONTAINING THEM
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
IL155805A0 (en) * 2000-12-18 2003-12-23 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists

Also Published As

Publication number Publication date
CA2507334C (en) 2013-05-07
CN100379730C (en) 2008-04-09
MXPA05005793A (en) 2005-08-16
WO2004050640A1 (en) 2004-06-17
RU2329255C2 (en) 2008-07-20
AU2003285321A1 (en) 2004-06-23
ZA200505109B (en) 2007-04-25
EP1569914B1 (en) 2009-02-18
EP1569914A1 (en) 2005-09-07
DE60326263D1 (en) 2009-04-02
CN1711248A (en) 2005-12-21
US20070167472A1 (en) 2007-07-19
CA2507334A1 (en) 2004-06-17
ATE423103T1 (en) 2009-03-15
ES2320649T3 (en) 2009-05-27
NO20052520L (en) 2005-06-27
US7452896B2 (en) 2008-11-18
IL168836A (en) 2010-12-30
RU2005120769A (en) 2006-02-27
AU2003285321B2 (en) 2010-04-08
KR101063042B1 (en) 2011-09-07
NO20052520D0 (en) 2005-05-25
KR20050086625A (en) 2005-08-30
NZ540937A (en) 2008-06-30
JP2006509775A (en) 2006-03-23
JP4769460B2 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
NO20051102L (en) Sulfonylamino-acetic acid derivatives
NO20052520D0 (en) New sulfamides
ATE286500T1 (en) 1,2,3,4-TETRAHYDROISOCINOLINE DERIVATIVES
BR0116237A (en) Compounds, pharmaceutical compositions, use of any one or more compounds, and process for the manufacture of pharmaceutical compositions
NO20042844L (en) 4- (piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as uprotensin II receptor antagonists
ATE435210T1 (en) TETRAHYDROISOCHINOLYLACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS
NO20034230L (en) 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
NO20032905L (en) New benzodiazepines and related heterocyclic derivatives useful as orexin receptor antagonists
SE0002102D0 (en) Chemical compound
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
NO20050932L (en) 1-pyridin-4-yl-urea derivatives
DOP2002000512A (en) SUCCINATE ACID SALTS OF 5,7,14-TRIAZATETRACICLO [10.3.1.0² ¹¹.04,9] HEXADECA-2 (11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
ATE383345T1 (en) QUINOXALIN-3-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS.
BR0211729A (en) Compounds, pharmaceutical compositions, process for manufacturing compounds, use of one or more compounds, and process for manufacturing pharmaceutical compositions
BRPI0509667B8 (en) compound, process for the preparation of a compound of formula (I), medicine and use of a compound
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
MXPA03000430A (en) Novel arylethene-sulfonamides.
ATE274515T1 (en) PYRAZOLOPYRIDINE DERIVATIVES
MXPA02006250A (en) Butyne diol derivatives.
UY26971A1 (en) NEW NEUROQUININE ANTAGONISTS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
BRPI0412425A (en) compounds, intermediates, pharmaceutical compositions, use of one or more compounds, and process for the manufacture of pharmaceutical compositions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014.